Completion and Settlement of Sale of Pain Away
Wellnex Life Limited
11 September 2026
ASX/AIM Announcement
11 September 2026
Completion and Settlement of Sale of Pain Away
Wellnex Life Limited (ASX/AIM: WNX) ("Wellnex Life" or the "Company") is pleased to announce that, further to the Company's announcement on 6 August 2026 and following the receipt of shareholder approval at the extraordinary general meeting held on 8 September 2026, all of the conditions precedent to the formal binding agreement to sell the Company's "Pain Away" business and assets to Mentholatum Australasia Pty Ltd (the "Transaction") have now been satisfied and the Transaction has now completed with the upfront purchase price settled.
Post completion of Transaction, Wellnex will continue to operate its established liquid soft gel analgesics business, built on the Company's own TGA marketing authorisations. The Company's contract manufacturing business is a capital-light business with growing international reach. The Board will use the cash proceeds from the Transaction to retire debt and to support the working capital requirements for the Company's continuing operations, and will review options that will deliver best values for shareholders. The Company will provide a further update to shareholders in due course.
This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).
The information contained within this announcement is deemed by the Company to constitute inside information pursuant to article 7 of EU Regulation 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended.
--- END ---
For further information, please contact:
Wellnex Life Limited (ASX/AIM:WNX)
Eric Jiang
Interim Executive Chairman
UK Investors
Strand Hanson (Financial & Nominated Advisor)
James Harris / Richard Johnson Tel: +44 (0) 20 7409 3494
Orana Corporate LLP (Joint Broker) swykeham@oranacorp.com
Sebastian Wykeham
S.P. Angel Corporate Finance LLP (Joint Broker) Tel: +44 (0)20 3470 0470
David Hignell / Vadim Alexandre
To learn more, please visit: https://wellnexlife.com.au/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.